Opioid-induced Constipation

FDA Approves Opioid Agonist Oliceridine

August 07, 2020


The indication limits the new opioid to clinical setting use—no take-home prescriptions.

Introducing Painkiller: A History of Crisis

March 01, 2020


The expert-led narrative series will seek to answer when and how the development of opioids led to a public health crisis.

FDA Approves Tegaserod Reintroduction for IBS with Constipation

April 01, 2019


Originally approved in 2002, tegaserod (Zelnorm) was withdrawn in 2007 due to potential safety concerns.

Synergy Pharmaceuticals Submits NDA for IBS-C Drug Plecanatide

March 27, 2017


Pharma submits sNDA for IBS-C drug plecanatide.

Chronic Idiopathic Constipation Gets New FDA Approved Treatment

January 19, 2017


The FDA today approved constipation remedy plecanatide.

Promising Results for Experimental Irritable Bowel Syndrome Drug

December 09, 2016


Patients suffering from irritable bowel syndrome with constipation (IBS-C) may benefit from a new drug, plecanatide, making its way through the approval pipeline.

Five Categories of Lower Gastrointestinal Functional Bowel Disorders in Revised Rome IV Criteria

May 24, 2016


The new Rome IV criteria classify the functional bowel disorders into five distinct categories, including irritable bowel syndrome (IBS), functional constipation, functional diarrhea, functional abdominal bloating/distention, and unspecified functional bowel disorder. A new category for opioid-induced constipation, which is distinct from the functional bowel disorders, has been added.

Rome IV Criteria Get Specific about Functional Gastroduodenal Disorders

May 24, 2016


Rome IV updates include more specific definitions and diagnostic criteria for functional gastroduodenal disorders such as functional dyspepsia, belching disorders, and nausea and vomiting disorders.